Korean Drug Co., Ltd. (KOSDAQ:014570)

Korean Drug Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	11,270	4,886	4,103	11,689	3,426	4,841
Short-Term Investments	25,126	25,111	14,897	5,067	22,990	-
Trading Asset Securities	-	-	-	-	-	23,039
Cash & Short-Term Investments	36,397	29,996	19,000	16,756	26,416	27,881
Cash Growth	43.90%	57.88%	13.39%	-36.57%	-5.25%	25.42%
Accounts Receivable	22,039	23,142	22,813	27,854	31,196	28,501
Other Receivables	12.46	25.94	77.99	154.04	264.21	481.69
Receivables	22,051	23,167	22,891	28,008	31,460	28,983
Inventory	16,596	15,526	20,168	18,341	13,775	12,894
Prepaid Expenses	11.57	29.72	26.21	29.68	15.8	14.88
Other Current Assets	286.91	346.48	841.25	291.26	949.19	677.81
Total Current Assets	75,342	69,066	62,925	63,426	72,617	70,450
Property, Plant & Equipment	19,983	20,653	22,054	22,999	18,607	13,999
Long-Term Investments	133.69	153.79	334.39	261.49	363.89	1,353
Other Intangible Assets	208.62	208.77	208.92	362.8	490.55	263.02
Long-Term Accounts Receivable	-	-	-0	-	-	-
Long-Term Deferred Tax Assets	1,032	1,245	1,208	1,015	1,163	820.32
Other Long-Term Assets	2,197	2,992	2,156	1,645	1,276	1,728
Total Assets	98,897	94,318	88,887	89,709	94,516	88,613

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4,039	1,243	570.28	1,921	4.55	3,213
Accrued Expenses	2,361	2,100	1,820	1,951	1,896	1,131
Current Portion of Leases	59.58	43.29	63.05	51.31	59.47	39.07
Current Income Taxes Payable	6,235	899.86	442.95	2,192	1,499	2,151
Other Current Liabilities	4,486	4,006	4,314	3,786	3,953	3,796
Total Current Liabilities	17,181	8,292	7,210	9,902	7,412	10,329
Long-Term Leases	22.09	14.55	17.91	16.26	21.73	15
Pension & Post-Retirement Benefits	-	-	-	345.17	263.64	-
Other Long-Term Liabilities	2,878	2,941	3,553	2,355	2,107	1,579
Total Liabilities	20,081	11,247	10,781	12,619	9,804	11,923

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	5,500	5,500	5,500	5,500	5,500	5,500
Additional Paid-In Capital	3,350	3,366	3,375	3,430	3,431	3,430
Retained Earnings	71,242	75,529	70,591	69,724	77,364	69,345
Treasury Stock	-1,277	-1,323	-1,360	-1,563	-1,583	-1,586
Comprehensive Income & Other	-0	-0	0	-0	-0	0
Shareholders' Equity	78,816	83,072	78,106	77,090	84,713	76,690
Total Liabilities & Equity	98,897	94,318	88,887	89,709	94,516	88,613

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	81.67	57.84	80.97	67.57	81.2	54.07
Net Cash (Debt)	36,315	29,939	18,919	16,688	26,335	27,826
Net Cash Growth	43.85%	58.25%	13.37%	-36.63%	-5.36%	25.47%
Net Cash Per Share	-	2767.49	1753.14	1547.64	2442.18	2546.94
Filing Date Shares Outstanding	-	10.82	10.81	10.79	10.78	10.78
Total Common Shares Outstanding	-	10.82	10.81	10.79	10.78	10.78
Working Capital	58,162	60,774	55,715	53,524	65,205	60,121
Book Value Per Share	-	7677.85	7222.25	7146.81	7855.42	7111.75
Tangible Book Value	78,607	82,863	77,897	76,727	84,222	76,427
Tangible Book Value Per Share	-	7658.56	7202.93	7113.17	7809.93	7087.35
Land	7,494	7,494	7,494	7,681	7,681	5,748
Buildings	6,111	14,955	14,955	14,955	11,264	11,264
Machinery	5,235	11,687	11,639	9,974	7,215	7,387
Construction In Progress	19.2	68.45	-	969.41	3,376	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error